Capital Fund Management (CFM)
MRTX

Capital Fund Management (CFM)’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Capital Fund Management (CFM)’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-42,056
Closed -$1.91M – 1782
2022
Q4 		$1.91M Sell
42,056
-10,094
-19% -$653K 0.01% 956
2022
Q3 		$3.64M Buy
52,150
+8,541
+20% +$632K 0.03% 653
2022
Q2 		$2.93M Sell
43,609
-6,706
-13% -$426K 0.03% 685
2022
Q1 		$4.14M Buy
50,315
+25,253
+101% +$2.58M 0.03% 651
2021
Q4 		$3.68M Buy
25,062
+8,932
+55% +$1.39M 0.03% 757
2021
Q3 		$2.85M Buy
16,130
+1,852
+13% +$298K 0.02% 785
2021
Q2 		$2.31M Buy
+14,278
New +$2.29M 0.02% 878
2020
Q3 		– Sell
-14,241
Closed -$1.63M – 1429
2020
Q2 		$1.63M Buy
14,241
+421
+3% +$40.8K 0.03% 562
2020
Q1 		$1.06M Sell
13,820
-8,120
-37% -$728K 0.02% 765
2019
Q4 		$2.83M Buy
21,940
+13,578
+162% +$1.31M 0.02% 734
2019
Q3 		$651K Buy
+8,362
New +$785K 0.01% 1161

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Capital Fund Management (CFM)'s MRTX Position: Q1 2023 in Review

Capital Fund Management (CFM) sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2023, closing a stake of 42,056 shares — an estimated $1.91M sold.

Capital Fund Management (CFM) first reported a position in MRTX in Q3 2019 and held it in 11 quarters. The position peaked at $4.14M in Q1 2022. 221 funds tracked by Wall St. Rank hold MRTX as of Q1 2023.

  • Capital Fund Management (CFM) reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 42,056 Mirati Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $1.91M.
  • Capital Fund Management (CFM) first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2019 and held it in 11 quarters.
  • Capital Fund Management (CFM)'s Mirati Therapeutics, Inc. Common Stock position peaked at $4.14M in Q1 2022.
  • 221 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2023, filed 15 May 2023.